U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Aligos Therapeutics

Market Cap: US$66.1m

A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

Vir Biotechnology

Market Cap: US$732.1m

A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Tango Therapeutics

Market Cap: US$772.1m

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

Bicara Therapeutics

Market Cap: US$658.0m

A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

NovaBay Pharmaceuticals

Market Cap: US$21.7m

Does not have significant operations.

Sonoma Pharmaceuticals

Market Cap: US$7.8m

Develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.

Lyell Immunopharma

Market Cap: US$225.2m

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

Upstream Bio

Market Cap: US$1.1b

A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.

Connect Biopharma Holdings

Market Cap: US$97.5m

A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.

Zenas BioPharma

Market Cap: US$863.7m

A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.

Viking Therapeutics

Market Cap: US$3.0b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Krystal Biotech

Market Cap: US$4.3b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Vertex Pharmaceuticals

Market Cap: US$101.8b

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

Harmony Biosciences Holdings

Market Cap: US$2.1b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

Absci

Market Cap: US$358.9m

Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

Tharimmune

Market Cap: US$18.5m

A clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States.

West Pharmaceutical Services

Market Cap: US$17.8b

Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Adicet Bio

Market Cap: US$59.4m

A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

Petros Pharmaceuticals

Market Cap: US$1.2m

A healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies.

Compass Therapeutics

Market Cap: US$578.2m

A clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

Evaxion

Market Cap: US$17.0m

A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.

Lixte Biotechnology Holdings

Market Cap: US$20.4m

A clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

Nautilus Biotechnology

Market Cap: US$82.3m

A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

SCYNEXIS

Market Cap: US$36.4m

A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.

Cullinan Therapeutics

Market Cap: US$408.2m

A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.

Allogene Therapeutics

Market Cap: US$246.3m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Maze Therapeutics

Market Cap: US$659.5m

A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.

Relay Therapeutics

Market Cap: US$689.6m

Operates as a clinical-stage precision medicines company.

Arvinas

Market Cap: US$558.7m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Mineralys Therapeutics

Market Cap: US$2.5b

A clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Creative Medical Technology Holdings

Market Cap: US$8.5m

A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

Korro Bio

Market Cap: US$263.7m

A biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.

Metsera

Market Cap: US$3.8b

A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

Sensei Biotherapeutics

Market Cap: US$11.1m

A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.

Monte Rosa Therapeutics

Market Cap: US$303.2m

A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

Nuvectis Pharma

Market Cap: US$166.0m

A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.